Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Drug-resistant EpilepsyFocal-Onset Seizures
Interventions
DRUG

Padsevonil

Padsevonil in different dosages.

OTHER

Placebo

Placebo will be provided matching Padsevonil.

Trial Locations (148)

19104

Ep0091 800, Philadelphia

19107

Ep0091 802, Philadelphia

20037

Ep0091 845, Washington D.C.

20817

Ep0091 818, Bethesda

21287

Ep0091 822, Baltimore

30303

Ep0091 873, Atlanta

32308

Ep0091 820, Tallahassee

32806

Ep0091 823, Orlando

33952

Ep0091 825, Port Charlotte

34471

Ep0091 809, Ocala

37232

Ep0091 835, Nashville

38018

Ep0091 838, Cordova

55102

Ep0091 817, Saint Paul

61637

Ep0091 832, Peoria

72205

Ep0091 810, Little Rock

75231

Ep0091 836, Dallas

78229

Ep0091 870, San Antonio

78681

Ep0091 824, Round Rock

78701

Ep0091 805, Austin

78758

Ep0091 844, Austin

85226

Ep0091 839, Chandler

92037

Ep0091 815, La Jolla

94115

Ep0091 801, San Francisco

96817

Ep0091 803, Honolulu

07601

Ep0091 806, Hackensack

10016-48

Ep0091 827, New York

75390-91

Ep0091 830, Dallas

Unknown

Ep0091 855, Box Hill

Ep0091 857, Clayton

Ep0091 850, Fitzroy

Ep0091 859, Herston

Ep0091 852, Melbourne

Ep0091 853, Melbourne

Ep0091 856, Randwick

Ep0091 854, Westmead

Ep0091 102, Bruges

Ep0091 101, Brussels

Ep0091 105, Ghent

Ep0091 100, Leuven

Ep0091 150, Blagoevgrad

Ep0091 151, Pleven

Ep0091 153, Pleven

Ep0091 152, Sofia

Ep0091 154, Sofia

Ep0091 155, Sofia

Ep0091 200, Greenfield Park

Ep0091 205, London

Ep0091 201, Montreal

Ep0091 254, Brno

Ep0091 255, Ostrava-Poruba

Ep0091 250, Prague

Ep0091 251, Prague

Ep0091 252, Prague

Ep0091 253, Prague

Ep0091 307, Clermont-Ferrand

Ep0091 309, Dijon

Ep0091 300, Lille

Ep0091 302, Montpellier

Ep0091 305, Paris

Ep0091 303, Rennes

Ep0091 306, Toulouse

Ep0091 361, Bad Neustadt an der Saale

Ep0091 365, Berlin

Ep0091 362, Bernau

Ep0091 363, Bielefeld

Ep0091 358, Bonn

Ep0091 350, Frankfurt am Main

Ep0091 360, Freiburg im Breisgau

Ep0091 364, Hamburg

Ep0091 368, Jena

Ep0091 366, Kork

Ep0091 357, Leipzig

Ep0091 353, Marburg

Ep0091 354, München

Ep0091 351, Münster

Ep0091 356, Osnabrück

Ep0091 367, Ravensburg

Ep0091 301, Strausberg

Ep0091 352, Tübingen

Ep0091 400, Budapest

Ep0091 403, Budapest

Ep0091 402, Debrecen

Ep0091 462, Bologna

Ep0091 450, Cagliari

Ep0091 461, Foggia

Ep0091 452, Milan

Ep0091 459, Pavia

Ep0091 453, Perugia

Ep0091 458, Pozzilli

Ep0091 454, Reggio Calabria

Ep0091 455, Roma

Ep0091 457, Roma

Ep0091 460, Roma

Ep0091 501, Asaka

Ep0091 511, Fukuoka

Ep0091 505, Hiroshima

Ep0091 513, Hōfu

Ep0091 507, Itami

Ep0091 503, Kodaira

Ep0091 514, Kyoto

Ep0091 512, Nagakute

Ep0091 510, Niigata

Ep0091 515, Saitama

Ep0091 509, Shizuoka

Ep0091 703, Kaunas

Ep0091 701, Vilnius

Ep0091 702, Vilnius

Ep0091 553, Culiacán

Ep0091 552, Mexico City

Ep0091 601, Gdansk

Ep0091 607, Grodzisk Mazowiecki

Ep0091 605, Katowice

Ep0091 608, Katowice

Ep0091 603, Krakow

Ep0091 604, Lublin

Ep0091 606, Nowa Sól

Ep0091 600, Poznan

Ep0091 609, Poznan

Ep0091 602, Świdnik

Ep0091 952, Santa Maria da Feira

Ep0091 004, Bardejov

Ep0091 001, Hlohovec

Ep0091 662, Alicante

Ep0091 651, Barcelona

Ep0091 652, Barcelona

Ep0091 658, Barcelona

Ep0091 664, Barcelona

Ep0091 668, Bilbao

Ep0091 666, Córdoba

Ep0091 650, Madrid

Ep0091 656, Madrid

Ep0091 660, Madrid

Ep0091 661, Madrid

Ep0091 659, Málaga

Ep0091 663, Seville

Ep0091 665, Terrassa

Ep0091 657, Valencia

Ep0091 667, Valencia

Ep0091 653, Valladolid

Ep0091 904, Eskişehir

Ep0091 900, Istanbul

Ep0091 901, Istanbul

Ep0091 752, Birmingham

Ep0091 751, Cardiff

Ep0091 756, Inverness

Ep0091 757, London

Ep0091 750, Manchester

Ep0091 753, Swansea

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03373383 - Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy | Biotech Hunter | Biotech Hunter